The role of thromboprophylaxis in cancer patients: emerging data.

ABSTRACT:

Purpose of review

Venous thromboembolism (VTE) is a frequent cause of morbidity and mortality in cancer patients. A significant proportion of cancer-associated VTE occurs in the ambulatory setting and is associated with poorer outcomes and reduced survival. Risk for VTE is influenced by patient, cancer and treatment-specific factors.

Recent findings

Recent studies have identified biomarkers associated with increased VTE risk in malignancy, including leukocyte and platelet counts, tissue factor, prothrombin split products, D-dimer, P-selectin, factor VIII and C-reactive protein. Recent and ongoing clinical trials have focused on VTE prophylaxis with low-molecular weight heparins in high-risk cancer outpatients, particularly those with pancreatic cancer. These studies have yie

SUBMITTER: Menapace LA 

PROVIDER: S-EPMC3088308 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature